New study: does starting this pill sooner save colitis patients from surgery?

NCT ID NCT07472309

Completed Disease control Sponsor: Xijing Hospital of Digestive Diseases Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at medical records of 81 people with severe ulcerative colitis to see if starting upadacitinib early works better than using it after other treatments fail. Researchers checked how many avoided surgery and achieved remission within 12 weeks. The goal is to find the best timing for this medication in real-world care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: upadacitinib (a pill that reduces inflammation)
What this could lead to: If successful, this could show that using upadacitinib early is better than waiting until other treatments fail, potentially reducing the need for surgery.
What could go wrong: This is a small, retrospective study (not a controlled trial), so results may not apply to everyone. Upadacitinib can have side effects like infections or blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE SEVERE ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE SEVERE ULCERATIVE COLITIS ULCERATIVE COLITIS (UC) UPADACITINIB

Contacts and locations

Locations

Xijing Hospital,Fourth Military Medical University

Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.